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esistance to antibiotics is of great social and eco-
nomic importance and is regarded as a threat to 
the national security of any country and the global 
community as a whole. Among the bacterial agents of dif-
ferent infections, resistance to some antibiotics can reach 
98%. Infections caused by antibiotic-resistant strains are 
distinguished by their significant duration, they often re-
quire hospitalization, they increase the length of hospital 
stay, and they often worsen the prognosis for a disease [1]. 
If the chosen medicines turn out to be ineffective, the doc-
tors have to use second- or third-order medicines, which 
are often rather expensive, less safe, and not always avail-
able. All these facts increase direct and indirect economic 
expenditures, as well as cause a risk of antibiotic-resistant 
strain propagation. causative agents of intracellular infec-
tions such as mycoplasmas and chlamydiae are character-
ized by high antibiotic resistance. treating mycoplasmosis 
and clamidiosis with a wide range of antibiotics is almost 
ineffective due to the quick formation of resistance to these 
medicines, and, as a result, the development of virus per-
sistence in the organism. 
In connection with this, it is essential to create alterna-
tive therapeutic agents which will not cause or limit antibi-
otic resistance. Antimicrobial peptides (AMPs) may be such 
therapeutic agents. they represent a unique and quite di-
verse group of compounds which make up a major compo-
nent of the natural immunity of all organisms [2]. compared 
to antibiotics, antibacterial peptides have the following ad-
vantages: a wider range of antibacterial action, functional 
activity at micromolar concentrations, the absence of virus 
resistance to antimicrobial peptides, and the synthesis ca-
pability of natural peptide analogues with altered biologi-
cal properties. the causative agent cannot become resistant 
to AMPs because of the unique mechanism of their action, 
which consists in the formation of channels and the follow-
ing fragmentation of the bacterial cell membrane. However, 
to date, all investigations devoted to the study of AMPs have 
focused on exogenic (synthesized) peptides, while the mech-
anism of AMPs synthesized directly in the infected cell is 
still unclear. We chose melittine as a model peptide, which is 
an amphipathic α-helical peptide (a major component in bee 
poison) [3]. 
In that review, we were the first to show the inhibition of 
such experimental infections as mouse Mуcoplasma hominis 
and Chlamydia trachomatis and broiler chicken Mycoplasma 
gallisepticum.
In this review, we used a pBI/mel2/rttA plasmid vec-
tor containing the melittine gene under the control of the 
tetracycline-dependent cMV promoter and the transacting 
rttA protein gene controlled by the early constitutive cMV 
promoter [4]. 
using this plasmid construction allows the expression 
level of the antimicrobial peptide genes in the organism to 
be accurately regulated with the help of different inducer 122 | ActA nAturAe |  № 1 2009
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doses, which is of great importance when the products of 
the expressed genes are toxic. 
We used female mice of the BALB/c line (6–8 weeks old 
and weighing 18–22 g). 
Before contamination with M.hominis, the mice were in-
jected subcutaneously with estradiol (Intervet uK, Great 
Britain) in doses of 0.5 mg per mouse (0.1 ml four times, 
with a week interval). Progesterone (Depo-Provera, Great 
Britain) was injected subcutaneously in a dose of 2.5 mg per 
mouse (0.1 ml, four days before contamination with C. tra-
chomatis).
M. hominis suspension (109 cell/ml titer) was injected (50 
mcl) into the mice intravaginally after the second estradiol 
injection. A fraction of C. trachomatis elementary bodies (106 
IFu/ml titer; IFu, inclusion-forming unit) was injected into 
the mice intravaginally (50 mcl) after progesterone injec-
tion. recombinant pBI/mel2/rttA plasmid vector was in-
jected intravaginally using the effectene transfection rea-
gent (Qiagen GmbH, Germany). the recombinant vector was 
injected twice: 24 h before infection with M. hominis or C. 
trachomatis and 14 days after infection in doses of 2 µg per 
DnA/mouse (25 mcl) with addition of 25 mcl of cacao oil to 
increase the suspension viscosity. Doxycycline hydrochlo-
ride (Icn Pharmaceuticals, Moscow, russia) was used as 
inducer of melittine gene transcription. the medicine was 
injected intramuscularly into the mice infected with M. ho-
minis and C. trachomatis in doses of 2 µg per mouse and 1 
µg per mouse, respectively, (50 mcl) at the moment of vector 
injection.  
the animals were subdivided into three groups (six mice 
in each group, two independent experiments). Group 1 was 
infected with M. hominis or C. trachomatis without pBI/
mel2/rttA plasmid vector or doxycycline. Group 2 was in-
jected with doxycycline in the corresponding dose with the 
following infection of M. hominis or C. trachomatis. Group 3 
was injected with pBI/mel2/rttA plasmid vector and doxy-
cycline followed by M. hominis or C. trachomatis.
to determine the M. Hominis titer after the pBI/mel2/
rttA plasmid vector injection, we prepared ten-fold dilut-
ed lavages from the upper urogenital tracts of the mice. to 
determine the C. trachomatis titer, we used the direct fluo-
rescence reaction and infected the Mccoy cell line with the 
vaginal lavages. 
the injection of the recombinant pBI/mel2/rttA vec-
tor and the following contamination of mice were finished 
by the M.hominis infection inhibition. the results may be 
seen in Fig. 1. the M. hominis titer in the vaginal lavages of 
Group 1 mice varied, decreasing from 5.9 to 2.4 log10 ccu/ml 
(сcu, color change unit) in four weeks. In the Group 3 mice, 
which were injected with the recombinant pBI/mel2/rttA 
vector and doxycycline before infection, the M. hominis titer 
was within 4.1–1.8 log10 ccu/ml. 
In the case of the pBI/mel2/rttA plasmid vector injec-
tion and the following infection of mice with С. trachomatis, 
the infection inhibition level was 45–80% (table 1).  
In spite of the fact that we did not achieve complete re-
covery of the mice from mycoplasmas and chlamydiae in the 
observation period, the rate of causative agent elimination 
was higher in Group 3 than in the control groups. three mice 
of Group 3 infected with M. hominis recovered from the vi-
rus on the 21st day after infection; in the control groups 1 
and 2, all mice had M. hominis. As for the mice infected with 
С. trachomatis, four mice from Group 3 were free from the 
virus on the 27th day after infection.
It should be noted that we did not obtain reliable statis-
tical differences in the titers of mice from Groups 1 and 2 
infected with M. hominis or С. Trachomatis, which, firstly, 
testifies to the absence of an uncontrolled expression of the 
melittine gene, and, secondly, to the fact that the chosen in-
ducer (doxycycline) concentration does not influence the in-
fection process development. 
to investigate the influence of recombinant vector injec-
tion on the development of the Mycoplasma gallisepticum 
infection, 60 21-day-old ross broiler chickens were marked 
and subdivided into four groups consisting of 15 chickens in 
such a way that the chickens’ average weight was analogous 
in each group on the basis of the Student t-test.
Group 1 was not infected with M. gallisepticum or in-
jected with the recombinant pBI/mel2/rttA plasmid vec-
tor. Group 2 was infected with M. gallisepticum, but the re-
Table 1. Influence of the recombinant pBI/mel2/rtTA plasmid vector 
injection on the C. trachomatis content in the vaginas of mice infected. 
Observation 
period
C. trachomatis titer in vaginal lavages of mice 
infected (number of C. trachomatis inclusions/ml) 
2 days  6 days 9 days
13 
days
16 
days 
20 
days
27 
days
group 1  12950 8490 4250 5220 2510 1070 1570
group 2 12600 9750 3930 4850 2140 980 1470
group 3 6850 2710 1920 2090 1080 370 350
Note: Differences between Group 3 and Groups 1 and 2 are reliable (P 
< 0.05).
Table 2. M. gallisepticum extraction from different parts of respiratory 
tract and internal organs.
Organ
group 
1
group 
2
group 
3
group 
4
Respiratory 
tract
Windpipe 0/14 a 14/14 14/14 14/14
Air pockets 0/14 12/14 10/14 14/14
Lungs 0/14 10/14 6/14 11/14
total quantity 
of reisolations
0 36 b 30 39
Internal 
organs
Liver 0/14 4/14 0/14 3/14
Milt 0/14 3/14 0/14 4/14
Kidneys 0/14 8/14 6/14 7/14
Heart 0/14 3/14 0/14 3/14
total quantity 
of reisolations
0 18  6 c 17
a Quantity of mycoplasma reisolations/total number of chickens
b Differences between Group 2 and Groups 3 and 4 are not statistically 
reliable.
c Differences between Group 3 and Groups 2 and 4 are statistically reli‑
able, p ≤ 0.01.reSeArcH ArtIcLeS
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combinant pBI/mel2/rttA plasmid vector was not injected. 
Group 3 was injected with the plasmid vector 5 h before 
infection with M. gallisepticum. Moreover, the mentioned 
chickens were injected intramuscularly with doxycycline 
(Icn Pharmaceuticals, Moscow, russia)—which acted as 
an inducer of melittine gene transcription—24 and 5 h be-
fore the infection in doses of 0.1 per chicken (in the volume 
of 100 mcl). Group 4 was injected with doxycycline (in the 
same dose and with the same intervals), followed by infec-
tion with M. gallisepticum. chickens of that group were not 
injected with the pBI/mel2/rttA plasmid vector. 
All chickens were subject to clinical, postmortem, immu-
nologic, and biological examinations. 
nine days after infection, the Groups 1 and 3 did not have 
any respiratory symptoms. At the same time, Groups 2, 4, 
and 5 were revealed to have respiratory rale. the second 
group was characterized by a reliable statistical decrease in 
average weight. M. gallisepticum extraction from the chick-
ens’ internal organs is of special interest (table 2). 
In spite of the fact that we did not obtain reliable differ-
ences in the frequency of M. gallisepticum reisolation from 
the chickens’ respiratory tracts in Groups 2 and 3 (table 
4), M. gallisepticum was detected only in 6 out of 56 inter-
nal samples. the livers, spleens, and hearts of that group of 
chickens did not contain M. gallisepticum.
undoubtedly, the most important mechanism of mem-
brane-active antimicrobial peptides, which leads to the inhi-
bition of mycoplasmosis and clamidiosis infections in the cell 
culture and in vivo, is their direct cytotoxic action on these 
bacteria [5]. 
Moreover, the in vitro processing of mycoplasmas with 
amphipathic peptides such as cecropin A, melittine, and 
magainin 2 depolarizes their plasmamembranes, alters their 
morphology, and decreases their mobility [6]. As was shown 
previously, the melittine gene expression in the HeLa cell 
culture results in a reduction of the transmembrane poten-
tial of the transfected cell [7], which is followed by a break-
down in the process of mycoplasma and chlamydia adhesion 
in the cell and, as a consequence, an interruption of the nor-
Fig. 1. Influence of the recombinant pBI/mel2/rtTA plasmid vector injec‑
tion on the M. hominis content in the vaginas of mice infected.
mal cycle of their development [8]. Moreover, it is quite pos-
sible that melittine expression alters the cell's cytoskeleton, 
and, as a consequence, breaks down the traffic of chlamydia 
inclusions.  
In spite of the fact that we did not manage to completely 
eliminate the virus from the urinogenital and respiratory 
tracts in our experiments, these data allow us to suggest that 
the recombinant plasmid vectors expressing the antimicro-
bial peptide genes may be considered as potential agents for 
preventing and treating micoplasmosis and clamidiosis. 
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